Quinn Lippmann
Urogynecology and Reconstructive Pelvic Surgery · Richmond, VANPI 1174750590
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,706 of the $3,461 with a category attached, or 78.2%. 29 manufacturers reported payments, led by Valencia Technologies Corporation at 25.3% of the total. Reporting peaked in 2022 at $1,971 and has fallen 97.5% since, to $49 in 2024. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in VA, where the typical reported total is $3,461.
Across 126 payments — averaging $27.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Valencia Technologies Corporation$877
- Dendreon Pharmaceuticals LLC$466
- Axonics, Inc.$369
- Astellas Pharma US Inc$176
- AbbVie$169
- Bayer$151
- plus $1K from 23 others
Across 4 payments — averaging $6250.00 each. An ownership or investment interest held by the physician or an immediate family member.
- Valencia Technologies Corporation$25K
What the payments were for
- Travel & lodging$75522%
- Food & beverage$2,70678%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Valencia Technologies Corporation | 3 | $877 |
| Dendreon Pharmaceuticals LLC | 21 | $466 |
| Axonics, Inc. | 8 | $369 |
| Astellas Pharma US Inc | 13 | $176 |
| AbbVie(2 entities) | 9 | $169 |
| Bayer | 8 | $151 |
| Medtronic(2 entities) | 3 | $144 |
| Endo Pharmaceuticals Inc. | 10 | $142 |
| Amgen | 9 | $139 |
| Antares Pharma, Inc. | 7 | $133 |
| Blue Earth Diagnostics | 4 | $100 |
| Boston Scientific | 2 | $90 |
| Urovant Sciences Inc | 5 | $82 |
| Coloplast | 2 | $59 |
| Johnson & Johnson | 3 | $53 |
| Merck | 2 | $41 |
| Urogen Pharma, Inc. | 2 | $32 |
| Accord Healthcare, Inc. | 2 | $31 |
| Therapeuticsmd, Inc. | 2 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Acessa Health Inc. | 1 | $26 |
| Teleflex LLC | 2 | $25 |
| Progenics Pharmaceuticals, Inc. | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
| Travere Therapeutics, Inc. | 1 | $16 |
| Novartis | 1 | $15 |
| Myovant Sciences Inc. | 1 | $15 |
| Myriad Genetic Laboratories, Inc. | 1 | $11 |
| Clarus Therapeutics Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- eCoin Device Kit$755
- Bulkamid$117
- INTERSTIM$105
How this compares
$3,461 in reported general payments places this provider in the 50th percentile of 29 urogynecology and reconstructive pelvic surgery providers in Virginia.
See all urogynecology and reconstructive pelvic surgery providers in Virginia →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 110 | $89,992 |
| GemtesaVibegron | 96 | $66,529 |
| EstringEstradiol | 42 | $25,676 |
| Mirabegron ErMirabegron | 52 | $18,816 |
| Estradiol | 327 | $15,327 |
| YuvafemEstradiol | 75 | $4,953 |
| Methenamine Hippurate | 31 | $2,798 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 66 | $724 |
| Cefpodoxime Proxetil | 11 | $408 |
| Ibuprofen | 39 | $365 |
| Ondansetron Hcl | 48 | $293 |
| Oxycodone Hcl | 50 | $291 |
| Fluconazole | 16 | $174 |
| Clobetasol Propionate | 12 | $172 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $71 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $176 | $89,992110 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 29 urogynecology and reconstructive pelvic surgery providers in Virginia.
Other urogynecology and reconstructive pelvic surgery in Richmond
- Meghana GowdaRichmond$5K
- Megan ShannonRichmond$3K
- Seyed ShobeiriFalls Church$116K
- Kurt McCammonVirginia Beach$67K
- Jeffrey WelgossAnnandale$50K
- Nathan GueretteMidlothian$20K
- Eric ChangStafford$11K
- Patricia MwesigwaArlington$8K
- Anna TrikhachevaPortsmouth$6K
- Walter von PechmannAnnandale$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.